Get Connected:


Latest News

Appropriate Post-Surgical Opioid Prescribing Examined
Guidelines needed to determine the appropriate length of opioid treatment after common surgical procedures.
Only 38% of parents are very confident that school staff can help a student with a suspected mental health problem.
Ingrezza is a selective VMAT2 inhibitor that was the first FDA-approved product indicated to treat adults with tardive dyskinesia.
Animas Corporation to cease operations and sale of insulin pumps.
Top news of the day from across the healthcare landscape.
Top articles of the week from The American Journal of Pharmacy Benefits.
A look at the top stories in pharmacy last week.
Employers may have the market power to demand transparency from pharmacy benefit managers.
View More >

From the Journals

For patients with psoriasis and/or psoriatic arthritis, actual-to-expected dosing ratios and costs were lower for etanercept than for ustekinumab.
An examination of payer coverage for multiple sclerosis drugs shows variation in how these drugs are covered and in the evidence that payers review to make these decisions.
Physician-, payer-, and patient-based organizations are increasingly developing frameworks that measure the value of a treatment and define it in terms of specific target audiences.
Medication compliance is associated with lower overall and disease-related healthcare costs in patients with moderate to severe rheumatoid arthritis receiving biologic therapies.
Clinician and patient understanding and access considerations represent the most significant hurdles inhibiting the uptake of biosimilars for inflammatory conditions.
Specialty pharmacies and managed care organizations will need to work together to truly balance the scale between cost and improved patient outcomes.
The distribution of infusible specialty medications comes with difficulties that must be addressed by pharmacies and payers.
Upcoming Partner Events